drugset / Trial / NCT01029795
A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to help answer the following research question(s): * To test if taking LY2599506 for 12 weeks controls blood sugar better than taking glyburide for 12 weeks. * To evaluate the safety of LY2599506 in participants with diabetes. * To determine if LY2599506 has the ability to control blood sugar in participants with diabetes. * To determine how much LY2599506 should be given to participants. * To determine if LY2599506 has an effect on a participant's weight. The study design consists of 4 study periods: a screening period, a 4-week dose adjustment period, an 8-week treatment period, and a 4-week follow up period.
Timeline
- Start
- 2010-02
- Primary completion
- 2010-06
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Glyburide | Small molecule | 5 mg | Oral |
| Comparator | Glyburide | Small molecule | 20 mg | Oral |
| Subject | LY2599506 | Unknown | 100 mg | Oral |
| Subject | LY2599506 | Unknown | 800 mg | Oral |